Kevin joined SV in 2018 as a Venture Partner. He is President and Chief Executive Officer of Enara Bio, an SV-created company.
Prior to joining SV, Kevin was Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore Ltd. In this role, he was responsible for shaping the Company’s corporate, R&D and growth strategies, as well as for overseeing business development. Kevin was also co-head of the Company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40m. Prior to joining Immunocore, Kevin was President, Chief Executive Officer of Quartet Medicine, a company he co-founded in late 2013 while working as an Entrepreneur-in-Residence at Atlas Ventures.
Kevin was also the Chief Operating Officer of Annovation Biopharma, which was sold to the Medicines Company in January 2015. He has also held senior executive R&D and corporate development roles at several biotech companies, including Vice President of Corporate Development at Kala Pharmaceuticals (NASDAQ:KALA) and, earlier in his career, spent time as an Investment Associate at PureTech Health (LSE: PRTC) an early stage venture capital firm.
Academic Credentials
PhD from the Biological Engineering Department at Massachusetts Institute of Technology; BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.
